PhoreMost makes key appointments to Board to advance development of next-generation degrader therapeutics

PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced Barbara Duncan has joined its Board as Chair, and…

Continue ReadingPhoreMost makes key appointments to Board to advance development of next-generation degrader therapeutics

Adverse waist-to-height ratio trajectories during childhood linked to early cardiometabolic risk

New research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May) reveals that adverse waist-to-height ratio trajectories (a marker for central obesity) during childhood…

Continue ReadingAdverse waist-to-height ratio trajectories during childhood linked to early cardiometabolic risk